Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Enrolling By Invitation1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07347379Enrolling By InvitationPrimary

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

NCT07607860Not ApplicableNot Yet RecruitingPrimary

Clinical Evaluation of the Adaptilens Accommodating IOL

Showing all 2 trials

Research Network

Activity Timeline